Imricor Medical Systems (IMR) Q1 2026 TU earnings summary

Executive summary

• Achieved major U.S. regulatory milestones with FDA clearance of NorthStar and Vision-MR Diagnostic Catheter in January 2026, supporting commercial expansion in the U.S.

• Expanded clinical trial capacity in the U.S. and Europe, adding high-volume centers to VISABL-AFL and VISABL-VT trials.

• Saw strong inbound commercial interest, with initial NorthStar sales expected in Q2 and growing engagement in the U.S., Europe, and Middle East.

Financial highlights

• Underlying operating cash outflows were US$5.9m in Q1 CY26, up from US$5.2m in Q4 CY25.

• Total operating cash outflow was US$7.8m, including a one-off investment in 40 RF-5000 generators and audit/legal costs for SEC registration.

• Cash receipts from customers were US$62k, up 140% from Q4 CY25, but still impacted by non-revenue-generating clinical trial enrollments.

• Cash and short-term investments totaled US$32.9m as of 31 March 2026.

Outlook and guidance

• Operating cash outflow is expected to trend back toward approximately US$6m in Q2 CY26.

• Clearance for NorthStar pediatric label expansion is anticipated in the current quarter, potentially accelerating U.S. commercial opportunities.

• Management expresses confidence in long-term growth, citing multiple catalysts and expanding market opportunities.